Marius Pharmaceuticals Submits KYZATREX® (Testosterone Undecanoate) CIII Capsules for Approval to Health Canada
30 juil. 2024 09h30 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company focused on developing innovative therapies for Testosterone Deficiency, is pleased to...
Marius Pharmaceuticals Supports AXYS 2023 Virtual Family Conference, Spotlighting KYZATREX™ for XY Chromosome Variations, such as Klinefelter’s Syndrome
20 juin 2023 08h30 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., June 20, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company specializing in therapies for hypogonadism or testosterone deficiency, announced today...
Male Hypogonadism Market to Reach $5.1 Billion by 2030, Claims Allied Market Research
28 juin 2022 17h00 HE
|
Allied Market Research
Portland, OR, June 28, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global male hypogonadism market generated $3.1 billion in 2020, and is expected to...